Advertisements



CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study

CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat. .....»»

Category: personnelSource: nytJun 12th, 2019

European shares gain for third straight session, AstraZeneca boosts

European shares rose for the third straight session on Tuesday, building on a recovery since late last week as British drugmaker AstraZeneca gained on positive data from a late-stage study. Francis Maguire reports......»»

Category: videoSource: reutersAug 20th, 2019

Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected in the second half of 2019 Presented interim data from CLASSICAL-Lung study.....»»

Category: earningsSource: benzingaAug 14th, 2019

Celsion announces data lock for interim analysis in OPTIMA Phase III study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 5th, 2019

Kodiak Sciences announces interim data from ongoing Phase 1B study of KSI-301

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 28th, 2019

Citi finds biotech executives jump ship ahead of bad drug trials

Analysis confirms what many on the Street were already thinking: biotech executives leaving ahead of late-stage clinical data often means the study will fail, according to one Citi’s Yigal... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkJul 2nd, 2019

Sarepta surges after Pfizer gene therapy data raises safety concerns

Shares of Sarepta Therapeutics Inc surged 15% on Friday after some safety concerns were raised in a small, early-stage study of a competing gene therapy for a rare muscle-wasting disorder from Pfizer Inc ......»»

Category: topSource: reutersJun 28th, 2019

Epizyme Announces Positive Interim Data on Lead Candidate

Epizyme (EPZM) announces positive interim data from an ongoing phase II study of its lead candidate, tazemetostat. .....»»

Category: smallbizSource: nytJun 24th, 2019

Portola presents interim data from Phase 2a study of cerdulatinib

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 19th, 2019

Despite Reporting Data For A Mid-Stage Study, La Jolla Has Several Other Irons In The Fire For 2019

Despite Reporting Data For A Mid-Stage Study, La Jolla Has Several Other Irons In The Fire For 2019.....»»

Category: topSource: seekingalphaJun 19th, 2019

CymaBay Tumbles On NASH Data, But One Must Take A Closer Look To Get The Full Picture

CymaBay Tumbles On NASH Data, But One Must Take A Closer Look To Get The Full Picture.....»»

Category: topSource: seekingalphaJun 18th, 2019

CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors

Shares of CymaBay Therapeutics Inc. plummeted 43% in premarket trade Tuesday after the biotech said data from an ongoing Phase 2 trial showed patients with nonalcoholic steatohepatitis (NASH) who were treated with investigational drug seladelpar did n.....»»

Category: topSource: marketwatchJun 11th, 2019

CymaBay reports topline 12-week data from ongoing Phase 2b study of seladelpar

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 11th, 2019

Athenex Rallies on Positive Early Data on Psoriasis Candidate

Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for .....»»

Category: worldSource: nytJun 10th, 2019

Amgen"s early-stage study of cancer treatment had "adverse events" in nearly half of its patients

Amgen Inc. said Wednesday data from phase 1 studies of an investigational bispecific T cell engager (BiTE) molecules, updated with investigational AMG 420 results for the treatment .....»»

Category: topSource: marketwatchJun 5th, 2019

Meet One of ASCO’s First Losers

Turning Point Therapeutics shares dipped on Friday after the firm posted interim data for its midstage study in ROS1-positive non-small cell lung cancer patients......»»

Category: blogSource: 247wallstMay 31st, 2019

Biogen announces new interim data from EVOLVE-MS-1 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 30th, 2019

What This Cara Therapeutics Late-Stage Study Could Mean for Chronic Kidney Disease

Cara shares jumped on Wednesday after the firm announced topline data from its late-stage trial in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus......»»

Category: blogSource: 247wallstMay 29th, 2019

OncoSec reports interim data from Keynote-890 study of breast cancer combination

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 22nd, 2019

Vaccinex Reports First Quarter 2019 Financial Results and Provides Corporate Update

Updated interim data from CLASSICAL-Lung study to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in.....»»

Category: earningsSource: benzingaMay 15th, 2019

Gilead shares slip 0.2% after second NASH trial fails

Shares of Gilead Sciences Inc. slipped 0.2% in premarket trade Thursday after the company said a late-stage study lo.....»»

Category: topSource: marketwatchApr 25th, 2019